背景:由于活性成分的代谢途径网络的复杂性,在合成网络上精确靶向合成任何活性成分是一个巨大的挑战。基于对一个物种中活性成分途径的完整分析,这一目标可以通过阐明途径中每种酶的功能差异并通过不同的组合来实现。木脂素是一类植物雌激素,在植物中大量存在,由于其结构多样性,在植物的各种生理活动中起作用。此外,木脂素为人类提供各种药用益处。尽管它们的价值,植物木脂素的低浓度限制了它们的提取和利用。最近,已经探索了木酚素生产的合成生物学方法,但是实现了大多数木脂素的合成,尤其是更有价值的木脂素苷,整个合成网络仍然不完整。
结果:通过评估各种基因构建方法和序列,我们确定pCDF-Duet-Prx02-PsVAO基因构建对生产(+)-松脂醇最有效,摇瓶发酵后产量可达698.9mg/L。基于(+)-松脂醇的稳定生产,我们在体内合成了下游代谢产物。通过比较不同的发酵方法,包括“一个单元格,“一罐”和“多细胞一罐”,我们确定“多细胞一锅”方法更有效地生产(+)-laricilesinol,(-)-secoisolariciresinol,(-)-matairesinol,和他们的糖苷产品。“多细胞一锅”发酵产生434.08毫克/升的(+)-拉冷素,96.81mg/L(-)-secoisolariciresinol,和45.14mg/L的(-)-马泰雷辛醇。随后,利用结合天然尿苷二磷酸葡萄糖(UDPG)模块的UDP-糖基转移酶(UGT)的严格底物识别特异性,用于体内合成糖苷产物,导致以下产率:()-松脂醇葡萄糖苷:1.71mg/L,(+)-赖利素-4-O-D-吡喃葡萄糖苷:1.3mg/L,(+)-赖利素-4'-O-D-吡喃葡萄糖苷:836µg/L,(-)-secoisolariciresinol单糖苷:103.77µg/L,(-)-马泰利辛醇-4-O-D-吡喃葡萄糖苷:86.79µg/L,和(-)-matairesinol-4\'-O-D-吡喃葡萄糖苷:74.5µg/L
结论:通过使用各种构建和发酵方法,我们在大肠杆菌中成功合成了板蓝根木脂素途径的10个产物,以丁香酚为底物。此外,我们通过组合不同的模块获得了各种各样的木酚素产品,为未来木酚素的高产生产奠定基础。
BACKGROUND: Due to the complexity of the metabolic pathway network of active ingredients, precise targeted synthesis of any active ingredient on a synthetic network is a huge challenge. Based on a complete analysis of the active ingredient pathway in a species, this goal can be achieved by elucidating the functional differences of each enzyme in the pathway and achieving this goal through different combinations. Lignans are a class of phytoestrogens that are present abundantly in plants and play a role in various physiological activities of plants due to their structural diversity. In addition, lignans offer various medicinal benefits to humans. Despite their value, the low concentration of lignans in plants limits their extraction and utilization. Recently, synthetic biology approaches have been explored for lignan production, but achieving the synthesis of most lignans, especially the more valuable lignan glycosides, across the entire synthetic network remains incomplete.
RESULTS: By evaluating various gene construction methods and sequences, we determined that the pCDF-Duet-Prx02-PsVAO gene construction was the most effective for the production of (+)-pinoresinol, yielding up to 698.9 mg/L after shake-flask
fermentation. Based on the stable production of (+)-pinoresinol, we synthesized downstream metabolites in vivo. By comparing different
fermentation methods, including \"one-cell, one-pot\" and \"multicellular one-pot\", we determined that the \"multicellular one-pot\" method was more effective for producing (+)-lariciresinol, (-)-secoisolariciresinol, (-)-matairesinol, and their glycoside products. The \"multicellular one-pot\"
fermentation yielded 434.08 mg/L of (+)-lariciresinol, 96.81 mg/L of (-)-secoisolariciresinol, and 45.14 mg/L of (-)-matairesinol. Subsequently, ultilizing the strict substrate recognition pecificities of UDP-glycosyltransferase (UGT) incorporating the native uridine diphosphate glucose (UDPG) Module for in vivo synthesis of glycoside products resulted in the following yields: (+)-pinoresinol glucoside: 1.71 mg/L, (+)-lariciresinol-4-O-D-glucopyranoside: 1.3 mg/L, (+)-lariciresinol-4\'-O-D-glucopyranoside: 836 µg/L, (-)-secoisolariciresinol monoglucoside: 103.77 µg/L, (-)-matairesinol-4-O-D-glucopyranoside: 86.79 µg/L, and (-)-matairesinol-4\'-O-D-glucopyranoside: 74.5 µg/L.
CONCLUSIONS: By using various construction and
fermentation methods, we successfully synthesized 10 products of the lignan pathway in Isatis indigotica Fort in Escherichia coli, with eugenol as substrate. Additionally, we obtained a diverse range of lignan products by combining different modules, setting a foundation for future high-yield lignan production.